Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences to progress with development of new HIV drug

Gilead Sciences to progress with development of new HIV drug

22nd April 2010

Gilead Sciences is to advance the development of a new combination therapy for HIV sufferers following encouraging results from a recent clinical trial.

The company’s collaborative partner Tibotec has published findings from two phase III studies of its drug TMC278 – which is a key component of the combination treatment – that shows its non-inferiority to the more established efavirenz.

Tibotec and Gilead plan to combine TMC278 with Gilead’s drug Truvada in order to create a once-daily single-tablet antiretroviral drug, which would become only the second product of its kind on the market if approved.

As a result of this development, Gilead is now looking to create a formulation of the Truvada and TMC278 combination which meets bioequivalence.

This will be followed by a bioequivalence study to ensure that the combination product results in the same amount of medication reaching the bloodstream as would be the case if the two drugs were administered separately.

Earlier this week, Gilead published its financial breakdown for the first quarter of 2010, during which the firm saw a year-on-year sales increase thanks in part to the strong performance of Truvada.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.